Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects (18 years of age or older) with MDS and low or intermediate-1 IPSS risk and del5q as a single abnormality, at the time of their screening and enrollment into the study~* Subjects must not have received any prior treatment course with any immunomodulating agent nor TPO-R agonists~* Subjects must be dependent on regular packed RBC transfusions, as defined by international working group 2006 criteria, and must have a PLT count taken within the 4 weeks prior to screening that is \>25 Gi/L.~* Absolute Neutrophil Counts (ANC) ≥ 0.5 GiL~* Resistant or refractory to erythropoetic stimulating agents (ESAs) and/or serum erythropoetin levels \> 500 miU/L~* Subjects must be ineligible or relapsed or refractory to receive treatment options of azacitidine and decitabine.~* Subjects must have PLT count and RBC and PLT transfusion data available over a period of 8 weeks prior to screening.~* During the 2 months prior to randomization, subjects must have a baseline BM examination including all of the following: cytomorphology, cytogenetics and histology~* ECOG Performance Status must be 0-3.~* The following clinical chemistries MUST NOT exceed the upper limit of normal (ULN) reference range: creatinine, ALT, AST, total bilirubin (except for Gilbert's Syndrome), gamma-gt and alkaline phosphatase. In addition, albumin must not be below the lower limit of normal (LLN) by more than 10%.~* If subject meets the criteria for childbearing potential:~  1. Negative pregnancy test in female subjects within the 3 days prior to Day 1 of 1st cycle and effective contraception for at least 4 weeks.~ 2. Subject is practicing an acceptable method of contraception (documented in chart). Female subjects (or female partners of male subjects) must either be of non-childbearing potential (hysterectomy, bilateral oophorectomy, bilateral tubal ligation or post-menopausal \>1 year), or of childbearing potential and use of an highly effective method of contraception from 2 weeks prior to administration of study medication, throughout the study, and 28 days after completion or premature discontinuation from the study.~* Criteria for women of non-childbearing potential: A female patient or a female partner of a male patient is considered to have childbearing potential unless she meets at least one of the following criteria:~  1. Age ≥ 50 years and naturally amenorrhoeic for ≥ 1 year (amenorrhoea following cancer therapy or during lactation does not rule out childbearing potential).~ 2. Premature ovarian failure confirmed by a gynaecologist~ 3. Previous bilateral salpingo-oophorectomy, or hysterectomy~ 4. XY genotype, Turner syndrome, uterine agenesis.~* Subject is able to understand and comply with protocol requirements and instructions.~* Subject has signed and dated informed consent.~Exclusion Criteria:~* MDS with intermediate-2 or high IPSS risk~* Additional cytogenetic abnormalities~* Transfusion independence (TI) by IWG 2006 criteria~* Absolute Neutrophil Count \< 0.5 Gi/L and/or Platelet counts \< 25 Gi/L~* History of treatment for cancer with systemic chemotherapy and/or radiotherapy within the last 2 years~* History of treatment with immunomodulatory drugs or other TPO-R agonists.~* Thrombophilia, pre-existing history of thrombosis, cardiovascular disease (including congestive heart failure, New York Heart Association \[NYHA\] Grade III/IV), or arrhythmia known to increase the risk of thromboembolic events (e.g. atrial fibrillation), or subjects with a QTc \>450 msec (QTc \>480 msec for subjects with Bundle Branch Block)~* Bone Marrow fibrosis that leads to an inability to aspirate marrow for assessment.~* Leukocytosis \>=25,000/uL prior to Day 1 of study medication.~* Monocytosis \> 1000/ uL prior to Day 1 of study medication.~* Female subjects who are nursing or pregnant (positive serum or urine Beta-human chorionic gonadotropin \[B-hCG\] pregnancy test).~* Women of childbearing potential unless all of the conditions of the Pregnancy Prevention Programme illustrated in sections 6.4 are met (see sections 6.4).~* Known hypersensitivity to lenalidomide.~* Current alcohol or drug abuse.~* Treatment with an Investigational Product within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.~* Active and uncontrolled infections.~* Subjects infected with Hepatitis B, C or Human Immunodeficiency Virus (HIV).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Eltrombopag) (Type: EXPERIMENTAL): Arm 1 is the active treatment arm
- Arm 2 (Placebo) (Type: PLACEBO_COMPARATOR): Arm 2 is the control arm

Based on this trial design, predict the completion outcome and termination type (if applicable).